Molecular Partners AG
MOLN
Helyezés a részvények között
#19470
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Részvényárfolyam
$3.99
Piaci kapitalizáció
$152.94M
Változás (1 nap)
0.33%
Változás (1 év)
15.06%
Ország
CH
Kereskedés Molecular Partners AG (MOLN)
Kategória
Healthcare
Piaci kapitalizációja Molecular Partners AG(MOLN)
Piaci kapitalizáció: $152.94M
October 2026-ban a Molecular Partners AG piaci kapitalizációja $152.94M. Ez alapján a Molecular Partners AG a világ 19470th legértékesebb vállalata a piaci kapitalizáció szerint. A piaci kapitalizáció egy tőzsdén jegyzett vállalat összes részvényének piaci értéke, amelyet gyakran használnak a vállalat értékének mérésére.
Molecular Partners AG piaci kapitalizációjának története 2016 és 2026 között
MOLN összehasonlítva az 5 legnépszerűbb stocks
